Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628705 | 0.83 | HTT (0.68) | HTTSMN1; SMN2CTBP2ALDH1A1LDHA | |
| SCHEMBL3175977 | 0.82 | HTT (0.61) | HTTSMN1; SMN2CTBP2ALDH1A1IDO1 | |
| SCHEMBL1525068 | 0.81 | HTT (0.66) | HTTSMN1; SMN2CTBP2ALDH1A1LDHA | |
| SCHEMBL240822 | 0.81 | KDM4E (0.74) | HTTSMN1; SMN2CTBP2ALDH1A1GAA | |
| SCHEMBL28709451 | 0.81 | HTT (0.66) | HTTSMN1; SMN2CTBP2ALDH1A1LDHA | |
| SCHEMBL48525 | 0.81 | HTT (0.66) | HTTSMN1; SMN2CTBP2ALDH1A1LDHA | |
| SCHEMBL498482 | 0.80 | F2RL1 (0.68) | SMN1; SMN2ALDH1A1POLBF2RL1NPC1 | |
| SCHEMBL9548104 | 0.80 | HTT (0.59) | HTTSMN1; SMN2CTBP2ALDH1A1IDO1 | |
| SCHEMBL10640045 | 0.79 | HTT (0.63) | HTTSMN1; SMN2CTBP2ALDH1A1LDHA | |
| SCHEMBL1067193 | 0.79 | HTT (0.63) | HTTSMN1; SMN2CTBP2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9521845-B2 | Beta-lactones as antibacterial agents | LUDWIG-MAXIMILIANS-UNIVERSITÄT-MÜNCHEN (DE) | 2016-12-20 | — | — | US | disclosed |
| US-20140163094-A1 | BETA-LACTONES AS ANTIBACTERIAL AGENTS | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2014-06-12 | — | — | US | disclosed |
| US-8669283-B2 | Beta-lactones as antibacterial agents | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2014-03-11 | — | — | US | disclosed |
| US-8563598-B2 | — | — | 2013-10-22 | — | — | US | disclosed |
| US-20110196027-A1 | BETA-LACTONES AS ANTIBACTERIAL AGENTS | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN | 2011-08-11 | — | — | US | disclosed |
| EP-2254574-A1 | BETA-LACTONES AS ANTIBACTERIAL AGENTS | Ludwig-Maximilians-Universität München (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009106211-A1 | BETA-LACTONES AS ANTIBACTERIAL AGENTS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2009-09-03 | — | — | WO | disclosed |
| US-5519051-A | AROMATASE INHIBITORS USEFUL FOR TREATMENT OF DISEASES CAUSED BY EXCESS OF ESTROGEN, FOR EXAMPLE, BREAST CANCER, UTERINE CANCER | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1996-05-21 | — | — | US | disclosed |
| EP-0582713-A1 | NOVEL OXA- OR AZASTEROID DERIVATIVE | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1994-02-16 | — | — | EP | disclosed |
| US-4571437-A | CATALYTIC HYDROGENATION REDUCTION AND REARRANGEMENT OF NITROBENZENE IN PRESENCE OF SULFUR COMPOUND | MALLINCKRODT, INC. (US) | 1986-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163094-A1 | BETA-LACTONES AS ANTIBACTERIAL AGENTS | ALG8, PGLS, GLA | HTT 2856/4885SMN1; SMN2 4873/4885CTBP2 1726/4885 |
| US-20110196027-A1 | BETA-LACTONES AS ANTIBACTERIAL AGENTS | ALG8, PGLS, GLA | HTT 2856/4885SMN1; SMN2 4873/4885CTBP2 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.